Eye­ing an IPO, Alzheon looks to raise $100M for a “de­risked” Alzheimer’s PhI­II

You don’t of­ten hear the word “de­risked” in a con­ver­sa­tion about an ex­per­i­men­tal ther­a­py for Alzheimer’s, but that’s the word Alzheon CEO Mar­tin To­lar choos­es to de­scribe where he’s at now with a new/old ther­a­py for the mem­o­ry-wast­ing ail­ment.

Af­ter rais­ing some $20 mil­lion in bridge fi­nanc­ing, To­lar’s small team jour­neyed to the Alzheimer’s con­fer­ence in Toron­to to spot­light the lat­est phar­ma­co­ki­net­ic da­ta they’ve put to­geth­er on ALZ-801, a pro­drug of tramiprosate, oth­er­wise known as Alzhemed, which like most Alzheimer’s drugs im­plod­ed in a Phase III study. And now he tells me that the biotech is well along the path to a new fi­nanc­ing round that can sup­port the $100 mil­lion bud­get need­ed to pay for two Phase III stud­ies, with a po­ten­tial IPO in the busi­ness plan.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.